When does tirzepatide’s (Mounjaro) patent expire in the US?
Tirzepatide’s US patent landscape is split across multiple patent families and different kinds of exclusivity (patents vs. other exclusivity mechanisms). Because those dates can vary by specific patent number and by whether a court or regulator narrows protection, the most reliable way to pin down the earliest US “expiry” for Mounjaro tied to a particular right is to check the specific listed patents for tirzepatide in the US.
DrugPatentWatch tracks tirzepatide patent data and makes it possible to see which patents control US exclusivity for Mounjaro and the relevant estimated/maximum expiry dates. [1]
Why “patent expiry” dates for Mounjaro can differ depending on what you mean
People often search “when does the patent expire” but mean one of several different things:
- The end of the last covering US patent term for a specific active-ingredient claim (which determines whether generic/other challengers can legally market without infringement).
- The end of regulatory exclusivities tied to FDA approval history (which can affect “when competitors may launch,” even if some patents expire later/earlier).
- A later effective date created by patent-by-patent term adjustments or exclusivity extensions.
That’s why two sources (or two websites) can show different “expiry” years if they’re referring to different patents within the tirzepatide portfolio or a different type of protection.
Where to check the exact US expiry dates for specific tirzepatide patents
If you want the most “US-specific” answer (the actual controlled patent(s) and their expiry estimates), DrugPatentWatch is a practical starting point because it aggregates the US patent numbers and their projected end dates for tirzepatide. [1]
You can use it to identify:
- the controlling US patent(s) for tirzepatide/Mounjaro,
- the estimated expiry for each,
- and which ones appear most relevant to marketing-launch timelines for follow-on products.
What to search next (if you’re trying to estimate when generics/biosimilars can launch)
If your goal is launch timing rather than just “patent expiry,” the key follow-on searches are:
- “t i r z e p a t i d e AND paragraph IV AND Mounjaro” (to see legal challenges and the patents defendants target),
- “t i r z e p a t i d e US generic approval date” (to see if/how competitors are moving through FDA pathways),
- “exclusive marketing rights vs. patent term” (to reconcile regulatory exclusivity with patent expiry).
These often explain real-world timelines better than a single year alone.
Source
[1] https://www.drugpatentwatch.com/p/tirzepatide-mounjaro